MarketPulse

Type 2 diabetes

5 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Biomea Fusion, Inc.

Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Cadrenal Therapeutics, Inc.

Cadrenal's Novel 12-LOX Inhibitor Shows Promise in Obesity and Diabetes Research

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.
CVKDclinical developmentGLP-1 medications
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
BenzingaBenzinga··Prnewswire

Global Diabetes Survey Reveals Market Gap: 80% Demand Predictive Tools Beyond CGM

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.
RHHBYhealthcare technologyType 1 diabetes